Where to next with animal health in Latin America? The transition from endemic to disease-free status

2017 ◽  
Vol 36 (1) ◽  
pp. 331-348
Author(s):  
H. ROJAS ◽  
J.R. ROMERO
Keyword(s):  
Latin America ◽  
Animal Health ◽  
Disease Free ◽  
Free Status

scholarly journals Development of a Safe and Highly Efficient Inactivated Vaccine Candidate against Lumpy Skin Disease Virus

Vaccines ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 4
Author(s):  
Janika Wolff ◽  
Tom Moritz ◽  
Kore Schlottau ◽  
Donata Hoffmann ◽  
Martin Beer ◽  
...  
Keyword(s):  
Skin Disease ◽  
Animal Health ◽  
Vaccine Virus ◽  
Lumpy Skin Disease ◽  
Virus Shedding ◽  
Clinical Protection ◽  
Inactivated Vaccines ◽  
Disease Free ◽  
World Organisation ◽  
Free Status

Capripox virus (CaPV)-induced diseases (lumpy skin disease, sheeppox, goatpox) are described as the most serious pox diseases of livestock animals, and therefore are listed as notifiable diseases under guidelines of the World Organisation for Animal Health (OIE). Until now, only live-attenuated vaccines are commercially available for the control of CaPV. Due to numerous potential problems after vaccination (e.g., loss of the disease-free status of the respective country, the possibility of vaccine virus shedding and transmission as well as the risk of recombination with field strains during natural outbreaks), the use of these vaccines must be considered carefully and is not recommended in CaPV-free countries. Therefore, innocuous and efficacious inactivated vaccines against CaPV would provide a great tool for control of these diseases. Unfortunately, most inactivated Capripox vaccines were reported as insufficient and protection seemed to be only short-lived. Nevertheless, a few studies dealing with inactivated vaccines against CaPV are published, giving evidence for good clinical protection against CaPV-infections. In our studies, a low molecular weight copolymer-adjuvanted vaccine formulation was able to induce sterile immunity in the respective animals after severe challenge infection. Our findings strongly support the possibility of useful inactivated vaccines against CaPV-infections, and indicate a marked impact of the chosen adjuvant for the level of protection.

Plants Used in Animal Health Care in South and Latin America

2010 ◽  
pp. 231-255 ◽  
Author(s):  
Rômulo Alves ◽  
Raynner Barboza ◽  
Wedson Souto
Keyword(s):  
Health Care ◽  
Latin America ◽  
Animal Health

scholarly journals Parallels, differences and lessons: a comparison of the management of foot-and-mouth disease and COVID-19 using UK 2001/2020 as points of reference

2020 ◽  
Vol 287 (1938) ◽  
pp. 20200906
Author(s):  
Keith Sumption ◽  
Theodore J. D. Knight-Jones ◽  
Melissa McLaws ◽  
David J. Paton
Keyword(s):  
Large Scale ◽  
Animal Health ◽  
Scientific Information ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Foot And Mouth ◽  
The Uk ◽  
Disease Free ◽  
Rapid Emergence ◽  
Critical Resources

Foot-and-mouth disease (FMD) is an extremely infectious viral infection of cloven-hoofed animals which is highly challenging to control and can give rise to national animal health crises, especially if there is a lack of pre-existing immunity due to the emergence of new strains or following incursions into disease-free regions. The 2001 FMD epidemic in the UK was on a scale that initially overwhelmed the national veterinary services and was eventually controlled by livestock lockdown and slaughter on an unprecedented scale. In 2020, the rapid emergence of COVID-19 has led to a human pandemic unparalleled in living memory. The enormous logistics of multi-agency control efforts for COVID-19 are reminiscent of the 2001 FMD epidemic in the UK, as are the use of movement restrictions, not normally a feature of human disease control. The UK experience is internationally relevant as few countries have experienced national epidemic crises for both diseases. In this review, we reflect on the experiences and lessons learnt from UK and international responses to FMD and COVID-19 with respect to their management, including the challenge of preclinical viral transmission, threat awareness, early detection, different interpretations of scientific information, lockdown, biosecurity behaviour change, shortage of testing capacity and the choices for eradication versus living with infection. A major lesson is that the similarity of issues and critical resources needed to manage large-scale outbreaks demonstrates that there is benefit to a ‘One Health’ approach to preparedness, with potential for greater cooperation in planning and the consideration of shared critical resources.

scholarly journals Foreword – special issue Mycotoxins in Latin America

2021 ◽  
Vol 14 (3) ◽  
pp. 241-245
Keyword(s):  
Latin America ◽  
Latin American ◽  
Animal Health ◽  
Ergot Alkaloids ◽  
Agricultural Products ◽  
Productivity Losses ◽  
Farm Structures ◽  
Warm Temperate ◽  
Latin American Countries ◽  
Milk And Dairy Products

Latin America with its considerable North-South extent is subject to climate that varies from tropical, subtropical and warm temperate to temperate. Different agricultural products are produced in the area including cereals, oilseeds, beans, fruits and nuts together with animal production including cattle for beef and milk, pigs, poultry and fish. The heterogeneity of agriculture in Latin America is reflected in the diversity of the region’s farm structures. While agriculture in the Southern Cone is dominated by large, commercial and export-oriented farms, particularly in Argentina and Brazil, besides increasingly in other countries like Uruguay, much of the rest of the region is characterised by smallholder and family agriculture. The contamination of agricultural products with mycotoxins has impact both human and animal health, as well as the economy due to losses related to rejections of agricultural products and by-products during trade. The economic burden related to the consumption of mycotoxins by animals is especially important, causing productivity losses up to the death of animals. The relevant mycotoxins are fumonisins, deoxynivalenol (DON) and zearalenone (ZEN) in cereals and cereal-based products, aflatoxins in cereals, oily seeds and nuts, aflatoxin M1 in milk and dairy products as well as ochratoxin A (OTA) in coffee, grapes and raisins. Co-occurrence of mycotoxins has also been observed mainly with aflatoxins and fumonisins in different Latin American countries (Torres et al., 2015). Advances on legislation in different countries including Argentina, Brazil, Chile, Mexico and Uruguay have been done to establish maximum limits for mycotoxins including aflatoxins, DON, ZEN, OTA, patulin and ergot alkaloids (ANVISA, 2011/2017; CAA, 2019/2021, Norma Oficial Mexicana, N.-243-S., 2010/2010; Reglamento Sanitario de los Alimentos, 2013).

Dose- and time-intensified ABVD without radiotherapy (RT) for advanced-stage Hodgkin lymphoma (HL) with mediastinal bulky disease (MBD).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8066-8066
Author(s):  
Gaetano Corazzelli ◽  
Filippo Russo ◽  
Ferdinando Frigeri ◽  
Francesco Volzone ◽  
Gaetana Capobianco ◽  
...  
Keyword(s):  
Event Free Survival ◽  
Cardiac Events ◽  
Bulky Disease ◽  
Free Survival ◽  
Nail Changes ◽  
Disease Free ◽  
Very High ◽  
Free Status

8066 Background: The role of consolidation RT on MBD after upfront chemotheraphy for advanced HL is debated, also given the supradditive iatrogenic risk. We present the results achieved in the subset of patients (pts) with MBD (max width > 1/3 of thoracic diameter) accrued in a phase II study of an intensified ABVD program without RT. Methods: The current analysis derives from the final evaluation of our trial for advanced HL (stage IIXB-IV) conducted from 06/2004 to 03/2010 (Russo et al, ASH 2009 abst 715). Pts were scheduled to 6 cycles of a ‘time-densified’ ABVD (3-week intercycle, drugs on days 1 and 11) with the first 4 cycles being also ‘dose-intensified’: doxorubicin (ADM) 35 mg/m2, days 1 and 11 and G-CSF on days 6-8 and 17-19. Results: Of 82 accrued pts, 39 had BMD at presentation. Median age was 29yrs (r 16-58); male 46%; stage IIB 48%, III 8%, IV 43%; B-sympt 87%, E-disease 53%; IP Score ≥3 51%. All pts completed the intensified program. Median actual dose intensities for ADM, bleomycin, vinblastine and dacarbazine were 23.12, 6.69, 3.96 and 245 mg/week, respectively; the increase over conventional ABVD was 85% for ADM and averaged 32% for the other agents. PET2 negativity was achieved in 36/39 (92%; 95% CI 79-98), complete responses (CR) in 37/39 [94%; 95% CI 82-99]. At a median f.u. of 54 mo.s (r 20-91) all pts are alive with an event-free survival of 89% (95% CI, 80-98). Events were: <CR (n=1, CS IVB), progression (n=1, CS IIIA), relapse [n=2; at 10 (CS IVA ) and 15 (CS IIB) months after treatment]; all these pts had isolated mediastinal recurrence. CTCAE v3.0 toxicity: Grade (G) 2 nail changes (31%), G2-G3 hemorrhoids (12%-3%), G3 infection (13%) and constipation (5%), G3-G4 stomatitis (7%-2%). No acute or delayed G3-G4 cardiac events, nor G3-G4 decline in pulmonary function (FEV1, DLCO,FEF25-75) were seen. Conclusions: Intensified ABVD can achieve PET2 negativity in a very high proportion of pts with MBD and ensure a long-term disease-free status even without RT. While results need confirmation on a randomized basis, the low mediastinal failure rate seems in line with recent suggestions that RT could be omitted in MBD when CR is achieved upon intensified chemotheraphy.

Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4618-4618
Author(s):  
Michele Reni ◽  
Hanno Riess ◽  
Eileen Mary O'Reilly ◽  
James Andrew Reeves ◽  
Elena Chiorean ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Disease Free Survival ◽  
Clinical Trial Design ◽  
Anticancer Therapy ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Independent Review ◽  
Independent Assessment ◽  
Disease Free ◽  
Free Status

4618 Background: APACT was a phase III trial of adjuvant nab-paclitaxel + gemcitabine ( nab-P + Gem) vs Gem alone in patients with resected pancreatic cancer (PC) and the first adjuvant PC trial to use independently assessed DFS as the primary endpoint (DFS by investigator review was a prespecified sensitivity analysis). We examined concordance between independent and investigator DFS review. Methods: For the independent assessment, reviewers determined recurrence by computed tomography or magnetic resonance imaging but were blinded to treatment and clinical data. Investigator-assessed DFS was based on all available data. Concordance was summarized by κ statistics. Patients who did not have recurrence or were alive were censored at the last tumor assessment date with disease-free status or the randomization date if the last tumor assessment with disease-free status was missing. Patients who received new anticancer therapy or cancer-related surgery prior to recurrence or death were censored at the date of last tumor assessment with disease-free status prior to the start of new anticancer therapy or cancer-related surgery or the randomization date if the last tumor assessment date with disease-free status prior to the start of subsequent new anticancer therapy or cancer-related surgery was missing. All censoring rules were the same for analysis of DFS by independent and investigator review. Results: Median DFS by independent review was 19.4 ( nab-P + Gem) vs 18.8 (Gem) months (hazard ratio [HR] 0.88; 95% CI, 0.73 - 1.06; P = 0.18); median investigator-assessed DFS was 16.6 ( nab-P + Gem) vs 13.7 (Gem) months (HR 0.82; 95% CI, 0.69 - 0.97; nominal P = 0.017). Moderate concordance was found between independent- and investigator-assessed DFS (Table); similar results were observed in the nab-P + Gem (concordance, 78%; κ coefficient, 0.56) and Gem alone (concordance, 76%; κ coefficient, 0.53) arms. Conclusions: The results reflect the complexities of defining the recurrence timepoint accurately and suggest that radiological review in the absence of clinical context is suboptimal for recurrence detection in resected PC. These findings may inform future clinical trial design. Registration: EudraCT (2013-003398-91); ClinicalTrials.gov (NCT01964430). Clinical trial information: NCT01964430 . [Table: see text]

scholarly journals Evaluation of the Worldwide Occurrence of Rabies in Dogs and Cats Using a Simple and Homogenous Framework for Quantitative Risk Assessments of Rabies Reintroduction in Disease-Free Areas through Pet Movements

2020 ◽  
Vol 7 (4) ◽  
pp. 207
Author(s):  
Guillaume Crozet ◽  
Julie Rivière ◽  
Laetitia Canini ◽  
Florence Cliquet ◽  
Emmanuelle Robardet ◽  
...  
Keyword(s):  
Annual Incidence ◽  
Risk Assessments ◽  
Similar Magnitude ◽  
High Burden ◽  
Canine Rabies ◽  
Major Threat ◽  
The Relationship ◽  
Disease Free ◽  
Free Status ◽  
Rabies Vaccination

Dog and cat rabies cases imported from rabies enzootic countries represent a major threat for areas that have acquired rabies-free status and quantitative risk analyses (QRAs) are developed in order to assess this risk of rabies reintroduction through dog and cat movements. Herein we describe a framework to evaluate dog and cat rabies incidence levels in exporting countries along with the associated uncertainty for such QRAs. For enzootic dog rabies areas (EDRAs), we extended and adapted a previously published method to specify the relationship between dog rabies vaccination coverage and canine rabies incidence; the relationship between dog and cat rabies incidences; and then to predict annual dog and cat rabies incidences. In non-enzootic dog rabies areas (nEDRAs), we provided annual incidence based on declared dog and cat rabies cases. For EDRAs, we predicted an annual incidence potentially greater than 1.5% in dogs and about ten times lower in cats with a high burden in Africa and Asia but much lower in Latin America. In nEDRAs, the occurrence of rabies was lower and of similar magnitude in dogs and cats. However, wildlife could still potentially infect dogs and cats through spillover events. This framework can directly be incorporated in QRAs of rabies reintroduction.

scholarly journals Irreparable Global Spread of Pathogens and International Trade – Facilitating Factors

2015 ◽  
Vol 48 (1-2) ◽  
pp. 37-43
Author(s):  
Václav Kouba
Keyword(s):  
International Trade ◽  
Animal Health ◽  
Long Distance ◽  
Premature Deaths ◽  
Animal Infection ◽  
Global Spread ◽  
Life On Earth ◽  
Imported Infections ◽  
Free Status ◽  
Free Animal

Abstract The worldwide trade in non-pathogen-free animals and their products has led to irreparable global spread of animal infections. Among factors supporting this spread belong: countless pathogen species able to reproduce and spread horizontally and to the next generations causing immense number of sufferings and premature deaths of affected animals and humans; increasing long distance export of animals and their products due also to not requiring by relevant international organizations healthy and innocuous pathogen-free commodities; illegal export/import of animals and their products; deficiencies related to diagnosis of pathogen-free status; inability to discover all imported infections, to control and eradicate them; international sanitary certificates without pathogen-free guarantee; inability of public animal health services to control on the spot the international trade with animal commodities; minimum of successfull animal infection eradications and absence of information about global spreading of pathogens to alert the countries in question. Huge daily flow of exported non-pathogen-free animal commodities conduces to permanent deterioration of global epizootiological situation. Irreparable man-made global spread of invisible pathogens with continuous multiplying sanitary, economic, social and ecological consequences represents a worldwide ecological disaster contributing to shortening life on Earth and survival of species, including self-destruction of humankind. Extraordinary existential significance requires international control of epizootics to be dealt with at the highest decision-making level of the United Nations Organization.

Sign in / Sign up

Export Citation Format

Share Document